[go: up one dir, main page]

MXPA05012323A - Sulfonamidas ciclicas para la inhibicion de gama-secretasa. - Google Patents

Sulfonamidas ciclicas para la inhibicion de gama-secretasa.

Info

Publication number
MXPA05012323A
MXPA05012323A MXPA05012323A MXPA05012323A MXPA05012323A MX PA05012323 A MXPA05012323 A MX PA05012323A MX PA05012323 A MXPA05012323 A MX PA05012323A MX PA05012323 A MXPA05012323 A MX PA05012323A MX PA05012323 A MXPA05012323 A MX PA05012323A
Authority
MX
Mexico
Prior art keywords
secretase
gamma
inhibition
cyclic sulfonamides
sulfonamides
Prior art date
Application number
MXPA05012323A
Other languages
English (en)
Inventor
Brian John Williams
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0311341A external-priority patent/GB0311341D0/en
Priority claimed from GB0327055A external-priority patent/GB0327055D0/en
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MXPA05012323A publication Critical patent/MXPA05012323A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/02—1,2-Thiazines; Hydrogenated 1,2-thiazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pyrane Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Los compuestos de la formula (I) (ver formula I) inhiben el procesamiento de APP a traves de gamma-secretasa, y por lo tanto son utiles en el tratamiento o prevencion de la enfermedad de Alzheimer.
MXPA05012323A 2003-05-16 2004-05-07 Sulfonamidas ciclicas para la inhibicion de gama-secretasa. MXPA05012323A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0311341A GB0311341D0 (en) 2003-05-16 2003-05-16 Therapeutic agents
GB0327055A GB0327055D0 (en) 2003-11-20 2003-11-20 Therapeutic agents
PCT/GB2004/002013 WO2004101539A1 (en) 2003-05-16 2004-05-07 Cyclic sulfonamides for inhibition of gamma-secretase

Publications (1)

Publication Number Publication Date
MXPA05012323A true MXPA05012323A (es) 2006-01-30

Family

ID=33420897

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05012323A MXPA05012323A (es) 2003-05-16 2004-05-07 Sulfonamidas ciclicas para la inhibicion de gama-secretasa.

Country Status (16)

Country Link
US (3) US7410964B2 (es)
EP (2) EP1644346A1 (es)
JP (1) JP4818114B2 (es)
KR (1) KR20060013404A (es)
AT (1) ATE386028T1 (es)
AU (1) AU2004238607B2 (es)
BR (1) BRPI0409969A (es)
CA (1) CA2525841C (es)
DE (1) DE602004011767T2 (es)
IL (1) IL171977A (es)
IS (1) IS8058A (es)
MX (1) MXPA05012323A (es)
NO (1) NO20055979L (es)
NZ (1) NZ542797A (es)
RU (1) RU2334743C2 (es)
WO (2) WO2004101538A1 (es)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0108591D0 (en) 2001-04-05 2001-05-23 Merck Sharp & Dohme Therapeutic agents
GB0120347D0 (en) 2001-08-21 2001-10-17 Merck Sharp & Dohme Therapeutic agents
GB0223039D0 (en) 2002-10-04 2002-11-13 Merck Sharp & Dohme Therapeutic compounds
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
NZ542797A (en) * 2003-05-16 2007-12-21 Merck Sharp & Dohme Cyclohexyl sulfones comprising an additional fused ring cyclic sulfonamide group suitable for inhibition of gamma-secretase
JP2008518955A (ja) 2004-11-02 2008-06-05 ノースウェスタン ユニバーシティ ピリダジン化合物および方法
US8362075B2 (en) 2005-05-17 2013-01-29 Merck Sharp & Dohme Corp. Cyclohexyl sulphones for treatment of cancer
EP1888078A2 (en) * 2005-05-17 2008-02-20 Merck Sharp & Dohme Ltd. Sulphone derivatives for treatment of cancer
GB0512049D0 (en) * 2005-06-14 2005-07-20 Merck Sharp & Dohme Chemical process
AU2007207481B2 (en) 2006-01-20 2012-08-23 Merck Sharp & Dohme Corp. Carbocyclic and heterocyclic arylsulfones as gamma secretase inhibitors
JP5379692B2 (ja) 2006-11-09 2013-12-25 プロビオドルグ エージー 潰瘍、癌及び他の疾患の治療のためのグルタミニルシクラーゼの阻害薬としての３−ヒドロキシ−１，５−ジヒドロ−ピロール−２−オン誘導体
US9126987B2 (en) 2006-11-30 2015-09-08 Probiodrug Ag Inhibitors of glutaminyl cyclase
CA2676715A1 (en) 2007-02-12 2008-08-21 Merck & Co., Inc. Piperazine derivatives for treatment of ad and related conditions
AU2008220785B2 (en) 2007-03-01 2013-02-21 Vivoryon Therapeutics N.V. New use of glutaminyl cyclase inhibitors
JP5667440B2 (ja) 2007-04-18 2015-02-12 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体
CN101754960A (zh) * 2007-07-05 2010-06-23 先灵公司 四氢吡喃并色烯γ-分泌酶抑制剂
WO2009011851A1 (en) * 2007-07-17 2009-01-22 Schering Corporation Benzenesulfonyl-chromane, thiochromane, tetrahydronaphthalene and related gamma secretase inhibitors
EP2291181B9 (en) 2008-04-18 2013-09-11 University College Dublin National University Of Ireland, Dublin Captodiamine for the treatment of depression symptoms
US20110263580A1 (en) * 2008-12-11 2011-10-27 Thomas Miller Method for treating alzheimer's disease and related conditions
US8691825B2 (en) 2009-04-01 2014-04-08 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
NZ598685A (en) 2009-09-11 2013-05-31 Probiodrug Ag Heterocylcic derivatives as inhibitors of glutaminyl cyclase
US8859776B2 (en) 2009-10-14 2014-10-14 Merck Sharp & Dohme Corp. Substituted piperidines that increase p53 activity and the uses thereof
US20120295923A1 (en) * 2010-01-29 2012-11-22 Pfizer Inc. Aminocyclohexanes and Aminotetrahydropyrans and Related Compounds As Gamma-Secretase Modulators
JP6026284B2 (ja) 2010-03-03 2016-11-16 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤
DK2545047T3 (da) 2010-03-10 2014-07-28 Probiodrug Ag Heterocycliske inhibitorer af glutaminylcyclase (QC, EC 2.3.2.5)
EP2560953B1 (en) 2010-04-21 2016-01-06 Probiodrug AG Inhibitors of glutaminyl cyclase
WO2011163330A1 (en) 2010-06-24 2011-12-29 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
CA2805265A1 (en) 2010-08-02 2012-02-09 Merck Sharp & Dohme Corp. Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)
HRP20191232T1 (hr) 2010-08-17 2019-11-01 Sirna Therapeutics Inc Inhibicija, posredovana rna interferencijom, ekspresije gena virusa hepatitisa b (hbv) korištenjem kratkih interferirajućih nukleinskih kiselina (sina)
US8946216B2 (en) 2010-09-01 2015-02-03 Merck Sharp & Dohme Corp. Indazole derivatives useful as ERK inhibitors
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
DK2632472T3 (en) 2010-10-29 2018-03-19 Sirna Therapeutics Inc RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS (SINA)
EP2654748B1 (en) 2010-12-21 2016-07-27 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
US8530670B2 (en) 2011-03-16 2013-09-10 Probiodrug Ag Inhibitors
EP2770987B1 (en) 2011-10-27 2018-04-04 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
EP2844261B1 (en) 2012-05-02 2018-10-17 Sirna Therapeutics, Inc. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
JP6280554B2 (ja) 2012-09-28 2018-02-14 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｅｒｋ阻害剤である新規化合物
AU2013352568B2 (en) 2012-11-28 2019-09-19 Merck Sharp & Dohme Llc Compositions and methods for treating cancer
KR102196882B1 (ko) 2012-12-20 2020-12-30 머크 샤프 앤드 돔 코포레이션 Hdm2 억제제로서의 치환된 이미다조피리딘
US9540377B2 (en) 2013-01-30 2017-01-10 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as HDM2 inhibitors
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
US10975084B2 (en) 2016-10-12 2021-04-13 Merck Sharp & Dohme Corp. KDM5 inhibitors
EP3461819B1 (en) 2017-09-29 2020-05-27 Probiodrug AG Inhibitors of glutaminyl cyclase
WO2019094311A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2019094312A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
CN112805006B (zh) 2018-08-07 2024-09-24 默沙东有限责任公司 Prmt5抑制剂
EP3833668B1 (en) 2018-08-07 2025-03-19 Merck Sharp & Dohme LLC Prmt5 inhibitors
EP3833667B1 (en) 2018-08-07 2024-03-13 Merck Sharp & Dohme LLC Prmt5 inhibitors
WO2021126731A1 (en) 2019-12-17 2021-06-24 Merck Sharp & Dohme Corp. Prmt5 inhibitors
US20230108114A1 (en) 2019-12-17 2023-04-06 Merck Sharp & Dohme Llc Prmt5 inhibitors
US12441730B2 (en) 2019-12-17 2025-10-14 Merck Sharp & Dohme Llc PRMT5 inhibitors
WO2022015670A1 (en) * 2020-07-14 2022-01-20 Nikang Therapeutics, Inc. Pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as cyclin-dependent kinase 2 inhibitors
AU2023336062A1 (en) 2022-09-02 2025-03-13 Merck Sharp & Dohme Llc Exatecan-derived topoisomerase-1 inhibitors pharmaceutical compositions, and uses thereof
CN120417935A (zh) 2022-10-25 2025-08-01 默沙东有限责任公司 依喜替康衍生的adc接头-载荷及其药物组合物和用途
AU2023397331A1 (en) 2022-12-14 2025-06-26 Merck Sharp & Dohme Llc Auristatin linker-payloads, pharmaceutical compositions, and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2833776A (en) * 1958-05-06 Aryl-substituted psperidylpropanols
US3992536A (en) * 1972-11-11 1976-11-16 Boehringer Ingelheim Gmbh Pharmaceutical compositions containing a 1-phenyl-2,2,4,4-C1 -C2 alkyl-3-[4-phenyl of pyridyl)-piperazino]-cyclobutanol-(1) and method of use
US3869434A (en) * 1973-11-19 1975-03-04 Phillips Petroleum Co Soluble arylene sulfide polymers
DE2528285A1 (de) * 1975-06-25 1977-01-20 Basf Ag Verfahren zur herstellung von 1,2,4-dihydrotriazin-4-oxid-spiro- (3,1')- eckige klammer auf oximino- (2')-cycloalkanen eckige klammer zu
FR2528433A1 (fr) * 1982-06-15 1983-12-16 Provesan Sa Nouveaux derives d'oxazinobenzothiazine-6,6-dioxyde, leur preparation et leur application en tant que medicaments
DE3347126A1 (de) * 1983-12-22 1985-07-11 Schering AG, 1000 Berlin und 4709 Bergkamen 11ss-aryl-estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate
DE4035961A1 (de) * 1990-11-02 1992-05-07 Thomae Gmbh Dr K Cyclische iminoderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
IL133604A0 (en) * 1997-07-16 2001-04-30 Novo Nordisk As Fused 1, 2, 4-thiadiazine derivatives, their preparation and use
HUP0201020A3 (en) 1999-02-26 2003-04-28 Bristol Myers Squibb Co Novel sulfonamide compounds and uses thereof
CA2404125C (en) 2000-03-20 2011-01-25 Merck Sharp & Dohme Limited Sulphonamido-substituted bridged bicycloalkyl derivatives
FR2812291B1 (fr) * 2000-07-28 2002-12-13 Adir Nouveaux derives de benzothiadiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP1334085B1 (en) 2000-11-02 2005-08-24 Merck Sharp & Dohme Ltd. Sulfamides as gamma-secretase inhibitors
GB0108592D0 (en) * 2001-04-05 2001-05-23 Merck Sharp & Dohme Therapeutic agents
GB0108591D0 (en) * 2001-04-05 2001-05-23 Merck Sharp & Dohme Therapeutic agents
EP1466898A4 (en) 2001-12-27 2005-12-07 Daiichi Seiyaku Co INHIBITORS OF THE PRODUCTION / SEPARATION OF BETA-AMYLOIDS PROTEINS
NZ542797A (en) * 2003-05-16 2007-12-21 Merck Sharp & Dohme Cyclohexyl sulfones comprising an additional fused ring cyclic sulfonamide group suitable for inhibition of gamma-secretase

Also Published As

Publication number Publication date
NZ542797A (en) 2007-12-21
IL171977A0 (en) 2006-04-10
CA2525841C (en) 2012-10-16
IL171977A (en) 2010-12-30
DE602004011767D1 (de) 2008-03-27
RU2005139398A (ru) 2006-04-10
IS8058A (is) 2005-09-30
EP1638951B1 (en) 2008-02-13
WO2004101538A1 (en) 2004-11-25
RU2334743C2 (ru) 2008-09-27
DE602004011767T2 (de) 2009-02-19
EP1644346A1 (en) 2006-04-12
WO2004101539A1 (en) 2004-11-25
US20080045515A1 (en) 2008-02-21
JP4818114B2 (ja) 2011-11-16
ATE386028T1 (de) 2008-03-15
KR20060013404A (ko) 2006-02-09
US7342009B2 (en) 2008-03-11
US20060281737A1 (en) 2006-12-14
JP2006528961A (ja) 2006-12-28
US20040230054A1 (en) 2004-11-18
BRPI0409969A (pt) 2006-04-25
CA2525841A1 (en) 2004-11-25
AU2004238607B2 (en) 2010-05-27
EP1638951A1 (en) 2006-03-29
AU2004238607A1 (en) 2004-11-25
NO20055979L (no) 2006-02-15
US7410964B2 (en) 2008-08-12

Similar Documents

Publication Publication Date Title
MXPA05012323A (es) Sulfonamidas ciclicas para la inhibicion de gama-secretasa.
GB0318447D0 (en) Therapeutic agents
DE60332137D1 (en) Cyclohexyl-sulphone als gamma-sekretase-inhibitoren
AU1074702A (en) Sulfamides as gamma-secretase inhibitors
GB0225475D0 (en) Therapeutic agents
GB0225474D0 (en) Therapeutic agents
GB0223040D0 (en) Therapeutic compounds
MY135477A (en) 2-(2,6-dichlorophenyl)-diarylimidazoles
ATE443043T1 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
MXPA05012268A (es) N-arilsulfonilpiperidinas enlazadas como inhibidores de la gamma-secretasa.
IS2517B (is) Notkun á setnum 2-amínótetralínum í fyrirbyggjandi meðferð á Parkinsons-veiki
DE60134874D1 (de) Benzodiazepin-derivate als gamma-secretase inhibitoren
UA83233C2 (ru) Замещенный 2-аминотетралин для лечения депрессии
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
NO20060020L (no) 3-fluorpiperidiner som NMDA/NR2B-antagonister
ATE446285T1 (de) Für die behandlung von alzheimer-krankheit und ähnlichen leiden geeignete 1-alkyl-3- thiosubstituierte indol-2-alkinsäuren
MY139368A (en) Novel cyclohexyl sulphones
DE602004019500D1 (en) 4-substituirte-5-cyano-1h-pyrimidin-6-(th)iones als als gsk-3-hemmer
TW200505836A (en) Cyclic sulfonamides for inhibition of gamma-secretase
ATE519740T1 (de) Tetrahydroindolderivate zur behandlung von alzheimer-krankheit

Legal Events

Date Code Title Description
FG Grant or registration